NW-7-295

N/A

Report date: 2025/04/02 11:26:24
NME

Base Information

Drug NameNW-7-295
Drug Alias NameNW-7-295
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionTyrosine-protein kinase BTK degraders
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGuangzhou Lupeng Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNewave Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A